Drug Profile
Insulin/pramlintide - Adocia
Alternative Names: ADO09; BC AsPram; BC Lis Pram; BC Pram Ins; BioChaperone Lispro Pramlintide; BioChaperone Pramlintide hIns; BioChaperone® AsPram; BioChaperone® Insulin Pramlintide; BioChaperone® LisPram; BioChaperone® Pramlintide Insulin; Insulin Lispro/pramlintide - Adocia; M1 pram - ADO09; M1pram; P037; Pramlintide/A21G human insulin; Pramlintide/insulin-lisproLatest Information Update: 05 Mar 2024
Price :
$50
*
At a glance
- Originator Adocia
- Developer Adocia; McGill University
- Class Antihyperglycaemics; Insulins; Macromolecular substances; Pancreatic hormones; Proteins
- Mechanism of Action Islet amyloid polypeptide stimulants; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Obesity; Type 1 diabetes mellitus
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Feb 2024 Adocia plans a phase III trial for Type 1 diabetes mellitus in the US (SC) in the third quarter of 2024
- 02 Nov 2023 Insulin/pramlintide - Adocia is available for licensing as of 02 Nov 2023. https://www.adocia.com/products/m1pram/
- 02 Nov 2023 Phase-II clinical trials in Obesity (unspecified route) (before November 2023) (Adocia Pipeline, November 2023)